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There are limited national epidemiological data for 
community-associated (CA)-Clostridium difficile infec-
tions (CDIs). Between March 2011 and March 2013, 
laboratories in England submitted to the Clostridium 
difficile Ribotyping Network (CDRN) up to 10 diar-
rhoeal faecal samples from successive patients with 
CA-CDI, defined here as C. difficile toxin-positive diar-
rhoea commencing outside hospital (or less than 48 
hours after hospital admission), including those cases 
associated with community-based residential care, 
with no discharge from hospital within the previous 
12 weeks. Patient demographics and C. difficile PCR 
ribotypes were compared for CA-CDIs in our study and 
presumed healthcare-associated (HA) CDIs via CDRN. 
Ribotype diversity indices, ranking and relative preva-
lences were very similar in CA- vs HA-CDIs, although 
ribotypes 002 (p ≤ 0.0001),020 (p = 0.009) and 056 
(p < 0.0001) predominated in CA-CDIs; ribotype 027 
(p = 0.01) predominated in HA-CDIs. Epidemic ribotypes 
027 and 078 predominated in institutional residents 
with CDI (including care/nursing homes) compared 
with people with CDI living at home. Ribotype diver-
sity decreased with increasing age in HA-CDIs, but not 
in CA-CDIs. Ribotype 078 CA-CDIs were significantly 
more common in elderly people (3.4% (6/174) vs 8.7% 
(45/519) in those aged < 65 and ≥ 65 years, respectively; 
p = 0.019). No antibiotics were prescribed in the previ-
ous four weeks in about twofold more CA-CDI vs HAs 
(38.6% (129/334) vs 20.3% (1,226/6,028); p < 0.0001). 
We found very similar ribotype distributions in CA- 
and HA-CDIs, although a few ribotypes significantly 
predominated in one setting. These national data 
emphasise the close interplay between, and likely 
common reservoirs for, CDIs, particularly when epi-
demic strains are not dominant.
Introduction
Clostridium difficile infection (CDI) has long been con-
sidered primarily to be a nosocomial disease, most 
notably associ ted with increased age, hospitalisation 
and antibiotic use [1]. There is, however, limited infor-
mation on the epidemiology of community-associ-
ated (CA)-CDI, but data suggest that the incidence of 
CA-CDI could be increasing [2-4]. However, variation in 
reported rates may be due to varying definitions and 
case ascertainment bias as a consequence of subopti-
mal or incomplete testing of community-based patients 
[5]. In general, it is also known that there is marked 
underascertainment of the causes of diarrhoea in the 
community [6,7].
In conjunction with mandatory reporting of CDI cases 
in England [8], additional surveillance includes vol-
untary submission of faecal samples to a centrally 
funded scheme (Clostridium difficile Ribotyping 
Network (CDRN) for England and Northern Ireland), 
which has provided specific data on circulating C. dif-
ficile PCR ribotypes since 2007. CDRN now examines 
over a third of all reported CDI cases in England [9]. 
A better understanding of the epidemiology of CA-CDI 
is required in order to achieve improved prevention 
and control of cases. We have therefore augmented 
the national CDRN surveillance scheme to compare the 
patient demographics and C. difficile ribotypes associ-
ated with healthcare (HA)- and CA-CDI over a two-year 
period, March 2011 to March 2013.
Methods
Community-associated-C. difficile infection 
surveillance scheme
During March 2011 to March 2013, hospital microbiol-
ogy laboratories in England were asked to send up to 10 
faecal samples to their regional CDRN laboratory from 
successive CDI cases who met the definition of CA-CDI: 
C. difficile toxin-positive diarrhoea (loose stools with 
no clear medical/surgical explanation) with onset of 
symptoms while outside hospital (or within the first 
48 hours of hospital admission), including those cases 
associated with community-based residential care, and 
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those without discharge from hospital within the previ-
ous 12 weeks [10,11]. More than 90% of (about 150) lab-
oratories were following national (two-stage testing) 
guidance for CDI diagnosis. All faecal samples submit-
ted were accompanied by a brief patient-based ques-
tionnaire (anonymised) that was completed at the local 
microbiological testing laboratory. The questionnaire 
recorded demographic data, details of hospitalisation, 
residency in a care/nursing home, and antibiotic expo-
sure (from patient records where available). Only the 
first half of the patient’s residential post code was col-
lected to permit potential geographical mapping, while 
retaining anonymity. C. difficile was cultured at the 
receiving CDRN laboratory. If the sample was C. difficile 
culture-negative then another case was recruited pro-
spectively. All C. difficile isolates were centralised at 
the CDRN Reference Laboratory in Leeds, England, and 
referred to the UK Anaerobe Reference Unit (UKARU) in 
Cardiff, Wales, for PCR ribotyping. Demographic and 
typing data were analysed at the CDRN Reference labo-
ratory, Leeds.
C. difficile culture, identification and PCR 
ribotyping
C. difficile isolates were recovered from faecal samples 
at by culture on modified Brazier’s cycloserine-cefoxi-
tin-egg yolk agar (Laboratory M, Bury, United Kingdom 
(UK)) without egg yolk and supplemented with 5 mg/L 
lysozyme (CCEYL) for 48 hours at 37 °C in an anaero-
bic atmosphere. C. difficile isolates were identified by 
their characteristic smell and colony morphology, fluo-
rescence under long-wave UV light and a latex aggluti-
nation test for C. difficile somatic antigen (Oxoid Ltd, 
Basingstoke, UK). 
PCR ribotyping was performed at UKARU as described 
previously [12]. Briefly, DNA was extracted from over-
night cultures of C. difficile using Chelex 100 resin 
(BioRad, Hemel Hempstead UK). The 16S-23S inter-
genic spacer regions were amplified using primers P3: 
5’-CTG GGG TGA AGT CGT AAC AAG G-3’ and P5: 5’-GCG 
CCC TTT GTA GCT TGA CC-3’. DNA fragments were con-
centrated before electrophoresis and resolved using 
3% Metaphor agarose (Cambrex Bioscience, Rockland, 
United States (US)).
Figure 1
Top 15 Clostridium difficile PCR ribotypes from cases of community-associated C. difficile infection (n = 703) and hospital-
associated C. difficile infectiona (n = 10, 754), England, March 2011–March 2013
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Cases of healthcare-associated Clostridium 
difficile infection
Comparative data for presumed HA-CDI cases (onset of 
symptoms ≥ 48 hours after admission to a healthcare 
facility or with onset of symptoms in the community 
within 12 weeks following discharge from a health-
care facility) [10,11] occurring during the same period 
were obtained from the results of routine CDRN test-
ing. C. difficile culture and ribotyping was performed at 
regional CDRN laboratories, with data collated by the 
CDRN Reference Laboratory in Leeds. In order to check 
the accuracy of the classification of routine CDRN 
cases as HA-CDI, demographic data were collected for 
all submitted samples in one region (Yorkshire and 
Humber).
Statistical methods
Univariate analyses were used to compare differences 
between categories using chi-squared test or Fisher’s 
exact test (where sample size was small, i.e. less than 
5, or less than 10 if only one degree of freedom). Median 
ages were compared by Mann–Whitney test. Ribotype 
diversity within groups was assessed using Simpson’s 
index, with 95% confidence intervals (CIs) demonstrat-
ing variance within groups. Univariate analyses were 
performed using SPSS version 19, and diversity analy-
ses using PAST version3.
Results
A total of 113 laboratories across England, all serving 
both hospitals and the community, referred 703 C. dif-
ficile toxin-positive (and C. difficile culture-positive) 
faecal samples from individual CA-CDI cases between 
March 2011 and March 2013 (i.e. median of six samples 
per laboratory, range: 1–25). The collected samples 
were approximately equally distributed over the two-
year period. A dataset of 11,479 CDRN records, for the 
same period, were used as presumed HA-CDI cases 
for comparison with CA-CDI cases. CA-CDI cases were 
predominantly female, elderly (≥ 65 years of age) and 
resident in their own home (Table).
The most frequently identified ribotype causing CA-CDI 
was RT002 (95/703; 13.5%) (Figure 1).
CA-CDI cases were significantly more likely than 
HA-CDIs to be due to ribotype 002 (p ≤ 0.0001). 
Although not as commonly isolated, ribotypes 020 
and RT056 were also significantly more likely to be 
found in CA-CDI cases than in HA-CDI cases (p = 0.009 
and < 0.0001 respectively). Ribotypes known to be 
associated with enhanced pathogen virulence and poor 
clinical outcome (078 and 027) were fourth and eighth 
most frequently identified ribotypes in CA-CDI cases, 
respectively. Notably, ribotype 027 was found signifi-
cantly more often in HA-CDI cases than in CA-CDI cases 
(p = 0.01). With the exceptions noted above, compari-
son of ribotypes causing CA- and HA-CDI showed a very 
similar ranking and prevalence distribution (Figure 1).
Cases referred to the national CDRN service (additional 
surveillance in conjunction with mandatorily reported 
CDI cases) were presumed to represent HA-CDIs. As 
these could conceivably contain CA-CDIs, however 
(for example, examined as part of outbreak investiga-
tions), we sought to compare the ribotype prevalences 
for CDRN-referred cases from one region in England 
(Yorkshire and Humber), comprising 14 distinct hospi-
tals, with known low-level community-based testing, 
with those for the remainder of the CDRN-referred cases 
in England during the same study period. All ribotype 
frequency pairs were within plus or minus 1.9% of 
each other, with the exception of ribotype 027 (6.6% 
(708/10,754) CDRN England, 17.8% (265/1,489) CDRN 
Y and H); this discrepancy was due to hospital-based 
outbreaks of 027 in the Y and H region.
Age of cases
Three quarters of the CA-CDI cases (519/693) were 
aged ≥ 65 years. Frequencies of the most prevalent 
ribotypes (top 15) found in the study are shown with 
respect to patient age in Figure 2.
The prevalence of ribotype 078 in cases of CA-CDI was 
significantly higher in elderly patients (3.4% (6/174) vs 
8.7% (45/519) in those aged < 65 vs ≥ 65 years, respec-
tively; p = 0.019). Similarly, ribotype 027 prevalence 
increased from 2.9% (5/174) to 4.4% (23/519) in elderly 
patients with CA-CDI, rising further to 5.6% (15/269) 
in those over 80 years of age, although this trend was 
not statistically significant. Proportions of cases with 
CA-CDI with ribotype 002 were found to increase with 
age, but again this was not statistically significant. 
Figure 2
The 15 most frequently identified Clostridium difficile 
PCR ribotypes from cases of community-associated C. 
difficile infection by age (< 65 years (n = 174) and ≥ 65 
years (n = 519)), England, March 2011–March 2013
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Conversely, although numbers were small, proportions 
of ribotypes 050, 018 and 017 were relatively larger 
in patients younger than 65 years than in patients 65 
years and older (4.0% (7/174), 2.9% (5/174) and 4.0% 
(7/174) vs. 1.7 (9/519), 1.7 (9/519) and 0.6% (3/519)) 
respectively. However, none of these were statistically 
significant (Figure 2). 
Median ages of cases with a particular ribotype were 
generally comparable for CA- and HA-CDI patients. 
Notably, although numbers were small, cases with 
CA-CDI due to ribotype 017 infection tended to be 
younger than corresponding HA-CDI patients (56.5 
years and 75 years, respectively; p = 0.13). 
Diversity of ribotypes decreased with increasing age 
in HA-CDI patients, while CA-CDI patients showed no 
such trend (Figure 3).
Place of residence
A fifth of the CA-CDI cases (125/525) in the study were 
associated with community-based residential care. 
Frequencies of the most prevalent ribotypes (top 15) 
found in the study with respect to patient residency 
and recent hospital admission are shown in Figure 4.
Patients with CA-CDI who were living in their own home 
and had no demonstrable hospital admission within the 
previous 12 months were classified as having no insti-
tutional or healthcare contact. Patients not residing in 
Figure 3
Diversity of Clostridium difficile PCR ribotypes (Simpson’s indices) for cases of community-associated C. difficile infection 
by (A) place of residence (n = 650), (B) time since last hospital admission (n = 627), (C) age (n = 693), and (D) for cases of 
hospital-associated C. difficile infection by age (n = 10,041)a, England, March 2011–March 2013
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their own home were classified as having institutional 
contact. Larger proportions of ribotypes 002, 078, 027 
and 001 were found among patients with institutional 
contact. Notably, prevalences of ribotypes 027 and 078 
were significantly higher in patients with institutional 
contact compared with those with no contact (10.4% 
(13/125) vs 2.9% (9/312) and 12.8% (16/125) vs 4.5% 
(14/312), respectively; both p < 0.001). Conversely, 
ribotype 015 was identified significantly more often in 
patients with no institutional contact versus those with 
institutional contact (11.2% (35/312) vs 4.8% (6/125), 
respectively; p = 0.034). Similar (but non-statistically 
significant) trends were also observed for ribotypes 
005 and 020 CDIs. Although numbers were small, it 
was interesting to note that ribotypes 050 and 018 
were completely absent in CA-CDI patients not residing 
in their own home. 
The diversity of ribotypes associated with CA-CDI 
cases residing in their own homes per se, was mark-
edly higher than that associated with care/nursing 
home residence, although this difference was not sta-
tistically signficant (Table,Figure 3).
Previous hospital stay
A quarter of CA-CDI cases (158/627) were identified as 
having been admitted to hospital within the previous 
three to six months. Frequencies of the most prevalent 
ribotypes (top 15) from cases in the study with respect 
to previous hospital stay are shown in Figure 5.
Proportions of CA-CDIs caused by ribotypes 078, 
020, 023 and 027 in patients with hospital admission 
within the previous three to six months were higher 
than in those with no evidence of hospital admission 
within the previous year, although these differences 
were only significant for ribotype 078 (12.0% (19/158) 
vs 4.5% (18/396); p = 0.005). Frequencies of several 
ribotypes, notably 002, 015 and 005, were found to be 
higher among patients who had no evidence of hospital 
admission within the previous year as compared with 
those admitted in the previous three to six months; 
only the difference in proportions of ribotype 005 was 
significant (9.8% (39/396) vs 2.5% (4/158); p = 0.003). 
Ribotype diversity was similar for CA-CDI cases with no 
evidence of hospital stay within the previous year com-
pared with those admitted in the previous three to six 
months (Table, Figure 3).
History of antibiotic use
History of antibiotic use was the most poorly com-
pleted part of the CA-CDI case questionnaires (47.5% 
(334/703) completed). For those with available antibi-
otic history data, CA-CDI cases were significantly more 
likely not to have received any antibiotics in the four 
weeks before their CDI episode when compared with 
HA-CDI cases (CDRN data) (38.6% (129/334) vs 20.3% 
(1,226/6,028); p < 0.0001). 
The three most common antibiotics/classes associ-
ated with CA-CDI cases were amoxicillin/clavulanic 
acid (16%; n = 61), amoxicillin/ampicillin (13%; n = 
51) and cephalosporins (6%; n = 23); 4% (n = 14) had 
received a fluoroquinolone. Notably, these data do not 
take into account the relevant frequencies of antibiotic 
prescribing. 
Frequencies of the most prevalent ribotypes (top 15) 
found in the study with respect to recent antibiotic use 
are shown in Figure 6.
A significantly higher proportion of ribotype 050 was 
associated with antibiotic use (0.78% (1/129) vs 5.8% 
(12/205); p = 0.013). For all other comparisons, p was 
greater than 0.05.
Patients with no institutional or healthcare contact 
and who did not receive any antibiotics in the previous 
four weeks, were classified as having no established 
risk factors for CDI. The prevalence of ribotype 002 
was higher in those patients with no established risk 
factors when compared with those with at least one 
known risk factor, although this was not statistically 
significant (14.5% (9/62) vs 12.5% (52/415); p = 0.662).
Discussion
To the best of our knowledge, this is the first large 
study in the UK to compare the epidemiology of 
CA- vs HA-CDI. In marked contrast to earlier reports, 
when HA-CDI was closely associated with a small 
range of epidemic ribotypes [1,13,14], we found very 
similar ribotype diversity indices for CA- and HA-CDI. 
Figure 4
Top 15 Clostridium difficile PCR ribotypes from cases of 
community-associated C. difficile infection by place of 
residence (community-based residential care) (n = 125) 
or their own home (n = 525), or their own home and no 
hospital admission with the previous 12 months (n=312), 
England, March 2011–March 2013
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Furthermore, the ranking and relative prevalences of 
ribotypes causing CA- and HA-CDIs were very similar. 
A relatively recent landmark study, using highly dis-
criminatory whole genome sequencing (WGS), showed 
that the majority of CDIs occurring between September 
2007 and March 2011 across a region in England did 
not represent case-to-case transmission of C. difficile 
[15]. Importantly, in that study, the rate of appearance 
of new, distinct C. difficile genotypes causing infec-
tions was constant, suggesting the existence of a large 
reservoir(s) of C. difficile. If correct, this would tend 
towards a similar distribution of ribotypes causing 
HA- and CA-CDI, (as found in this study) assuming that 
there are no powerful selection pressures or niches for 
particular ribotypes that could promote CDIs in one 
setting versus the other.
In England, a pragmatic definition has been used in 
national surveillance to apportion CDI cases between 
hospitals (symptom onset after 72 hours following 
admission) and the community (symptom onset in 
the community or within the first 72 hours following 
admission to hospital) [8]. However, this definition may 
exaggerate numbers of cases with apparent CA-CDI as 
it fails to take into account recent previous hospital 
admission. Multiple, often large outbreaks were typical 
around the peak incidence of CDIs in the UK in 2007–
08; since then there has been a ca 70–80% decrease 
in case frequency [13,14] This followed intensive pub-
lic health campaigns that included multiple infection 
prevention and control measures designed to reduce 
transmission of C. difficile and alter prescribing of anti-
microbials [16]. One of the most striking aspects of 
this control programme was the substantial decrease 
in prevalence of ribotype 027 CDIs. In 2007–08, this 
ribotype caused more than 50% of CDIs in England 
referred to the CDRN; in subsequent 12-month periods 
the corresponding proportions were 36% (in 2008–09), 
22% (in 2009–10), 13% (in 2010–11), and 9% (in 2011–
12) [13]. The control of this epidemic strain, which is 
associated with poor clinical outcome [17,18], has been 
paralleled by an increased heterogeneity of ribotypes 
causing CDIs [13]. This observation is also consist-
ent with the similar distributions of strains found to 
be causing CA-CDIs and HA-CDIs in this study. Earlier 
studies in Sweden (1998 and 2004) also reported simi-
lar distributions of ribotypes among nosocomial and 
community settings [19,20]. Such data likely reflect the 
close interplay between hospital and community set-
tings at times of relatively low levels of hospital-based 
CDI case-to-case transmission. 
While C. difficile ribotype distributions were similar 
among cases of CA- and HA-CDI in our study, there 
were some notable differences. CA-CDI cases were 
significantly more likely than HA-CDI cases to be due 
to ribotype 002 and (less commonly) to ribotypes 020 
and 056. Conversely, ribotype 027 was found signifi-
cantly more often in HA-CDI cases than CA-CDI cases. 
Ribotype 002 is a relatively frequent cause of HA-CDI 
and is among several other long-recognised ribotypes, 
including 015, 014, 020 and 078, which have become 
more common in the UK, concurrent with the demise 
of epidemic ribotypes such as 027, 106 and 001 [9,13]. 
Studies have repeatedly demonstrated a lower median 
age in patients with CA-CDI compared with HA-CDI [19-
22]. However, we did not find a statistically significant 
difference. Age-related differences may be confounded 
Figure 5
Top 15 Clostridium difficile PCR ribotypes from cases of 
community-associated C. difficile infection by status of 
previous hospital admission (within 3–6 months of their 
C. difficile infection episode (n = 158) and those with 
no record of hospital admission within the previous 12 
months (n = 396)), England, March 2011–March 2013
0
2
4
6
8
10
12
14
16
002 015 014 078 005 020 023 027 001 050 018 056 126 070 017
PCR ribotype
Pe
rc
en
ta
ge
 o
f t
yp
ed
 is
ol
at
es
 in
 
th
e 
sp
ec
ifi
ed
 g
ro
up
 o
f c
as
es
Admitted within previous 3–6 months    
No admission within previous 12 months    
Ribotype proportions are expressed as percentages of the total 
number of ribotyped C. difficile isolates from patients admitted 
to hospital within the previous three to six months and those 
with no evidence of hospital admission within the previous 12 
months.
Figure 6
Top 15 Clostridium difficile PCR ribotypes from cases 
of community-associated C. difficile infection by history 
of antibiotic use during 4 weeks before their C. difficile 
infection episode (no antibiotics (n = 129) and one or 
more antibiotics (n = 205)), England, March 2011–March 
2013
0
2
4
6
8
10
12
14
16
002 015 014 078 005 020 023 027 001 050 018 056 126 070 017
PCR ribotype
Pe
rc
en
ta
ge
 o
f t
yp
ed
 is
ol
at
es
 in
 
th
e 
sp
ec
ifi
ed
 g
ro
up
 o
f c
as
es One or more antibiotics
No antibiotics 
Ribotype proportions are expressed as percentages of the total 
number of ribotyped C. difficile isolates from patients who 
received no antibiotics and those who received one or more 
antibiotics.
7www.eurosurveillance.org
by ascertainment bias, including testing policy in hos-
pital versus community settings. We speculate also that 
differences between studies with respect to age may be 
driven by ribotype distribution in population cohorts. 
Data from our study showed that infections associated 
with certain ribotypes (002, 027, 078) were more com-
mon in patients aged ≥ 65 years. Notably, CA-CDIs due 
to ribotype 078 were ca 2.5-fold more likely to affect 
an individual aged ≥ 65 years. Median ages of CA-CDI 
cases and HA-CDI cases were very similar for infections 
due to ribotypes 002, 027 and 078. A Dutch study in 
2008 found a significant difference in the median age 
of CDI cases due to ribotypes 078 and 027 (67.4 vs 73.5 
years, respectively) [21]. In our study, although median 
age was lower for cases due to ribotype 078 (80 years), 
vs 82 years for ribotype 027, this difference was not 
statistically significant. Although numbers were small, 
ribotype 017-associated CA-CDIs were more than 
three times more likely to affect a younger individual. 
Additionally, the median age of patients with ribotype 
017-associated CDI was significantly lower in CA-CDI 
patients than in corresponding HA-CDI patients, sug-
gesting that a true association may exist between 
ribotype 017 infections and the younger patient in a 
Table
Patient-based questionnaire data and Clostridium difficile PCR ribotype diversity (Simpson’s index) for cases of community-
associated C. difficile infection (n = 703) and cases of healthcare-associated C. difficile infectiona (n = 11,479), England, 
March 2011–March 2013
Case characteristics
Number
Cases of CA-CDI with available data
Simpson’s index (95% CI) Cases of HA-CDI with available data
PCR ribotype diversity
Total 
number per 
category
% Number Total number per category % CA-CDI HA-CDI
b
Sex 
Male 234
701 
33 4,855 11,289 
For Simpson’s, 
n = 9,812b
43 0.94  (0.92–0.95)
0.94  
(0.94–0.94)
Female 467 67 6,434 57 0.94  (0.93–0.95)
0.94  
(0.94–0.95)
Age in years 
< 65 174
693 
25 2,805
11,387 
For Simpson’s, 
n = 10,041b
25 0.94  (0.93–0.95)
0.95  
(0.94–0.95)
65–80 250 36 3,843 34
0.93  
(0.92–
0.94)
0.94  
(0.94–0.95)
> 80 269 39 4,739 42 0.94  (0.93–0.95)
0.94  
(0.94–0.94)
Place of 
residence
Community-
based 
residential care
125
650 
19 NA NA NA
0.92  
(0.90–
0.94)
NA
In own home 525 81 NA NA NA 0.94  (0.94–0.95) NA
Previous 
hospital stay, 
from sample 
date
Within less than 
the previous 
3–6 months
158
627
25 NA NA NA 0.94  (0.93–0.95) NA
Within previous 
6 to 12 months 73 12 NA NA NA
0.93  
(0.90–
0.94)
NA
No evidence of 
hospital stay 
within previous 
12 months
396 63 NA NA NA 0.94  (0.93–0.95) NA
Antibiotics 
received, 
within 
previous 4 
weeks
None 129
334
39 1,226
6,028 
For Simpson’s, 
n = 5,279b
20 0.93  (0.91–0.94)
0.93  
(0.93–0.94)
1 134 40 2,066 34 0.94 (0.93–0.95)
0.94  
(0.94–0.94)
2 48 14 1,411 23
0.94  
(0.90–
0.95)
0.94  
(0.94–0.94
3 or more 23 7 1,325 22
0.91  
(0.86–
0.93)
0.94  
(0.94–0.95)
CA: community-associated; CDI: Clostridium difficile infection; CI: confidence interval; HA: hospital-associated; NA: not available.
a HA-CDI data were obtained from the Clostridium difficile Ribotyping Network (CDRN).
b Simpson’s index was calculated where a ribotype result was available.
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community setting. We also found that ribotype diver-
sity decreased with increasing age in HA-CDI patients, 
while CA-CDI patients showed no such trend.
Recent US studies (2013–15) found that about a third of 
CDI cases were CA-CDIs [3,4,23]. However, the increas-
ing use of nucleic acid amplification tests (NAATs) alone 
for the diagnosis of CDI may be confounding US data, 
given the clear potential for large overestimates of CDI 
incidence by this sensitive but poorly specific diag-
nostic approach [24]. Indeed, use of NAATs was found 
to significantly correlate with higher reported CA-CDI 
incidence [3]. By contrast, at the time of our study, 
79% and 94% of UK hospitals in 2011–12 and 2012–13, 
respectively, were using an optimised method (screen-
ing test followed by a toxin test) for CDI diagnosis [24]. 
In the US, between 2009 and 2011, ca 40% of cases 
defined as CA-CDI had high-level exposure to health-
care (i.e. surgery, dialysis, emergency or urgent care 
visit, inpatient care with no overnight stay, or health-
care personnel with direct patient care), despite no 
hospital admission in the previous 12 weeks [4]. A fur-
ther ca 40% had low-level healthcare exposure (i.e. an 
outpatient visit with a physician or dentist). Thus, only 
ca 20% of CA-CDI cases had no recorded healthcare 
contact in the previous 12 weeks. Of note, HA-CDI was 
taken to include cases occurring in nursing homes (and 
acute care hospitals or long-term acute care hospitals). 
There is a key issue regarding consistency between 
studies and healthcare systems concerning defini-
tions of ‘nursing homes’. In the US, there are more 
than 15,000 nursing homes, each averaging over 100 
licensed beds [25]. By contrast, care homes in England 
(about 17,500) with nursing capability (n = ca 4,000) 
are about half the size of their US counterparts; typi-
cally both nursing and residential care are provided 
within the same facility [26-28]. In England, about 4% 
(ca 375,000) of the population aged  over 65 years live 
in care/nursing homes, rising to almost 20% of those 
aged ≥ 85 years. Thus, a sizeable minority of elderly 
people live in care homes, but determining whether 
individuals are receiving nursing as opposed to resi-
dential care is problematic, given that care needs may 
fluctuate. Subjects receiving residential care are not 
receiving healthcare per se, but instead are helped 
with normal daily living activities. This highlights the 
dilemma of how best to categorise subpopulations res-
ident in care homes.
A limitation of our study is that we did not ascertain 
the level of nursing received by CA-CDI cases in care 
homes. We chose to define CA-CDI cases to include 
non-hospital-associated cases living in care homes, 
noting that the great majority of residents in such set-
tings are not receiving nursing care [26-28]. However, 
by examining subpopulations resident in the commu-
nity in care homes, we did demonstrate a clear pre-
dominance of epidemic ribotypes, notably 027 and 
001, in patients with institutional contact compared 
with those living in their own home. High prevalence 
of ribotype 027 CDIs in nursing home residents has 
been reported in Germany in 2012 [29], but data in this 
setting are limited [30]. Carriage of C. difficile, CDI and 
subsequent transmission of the pathogen are more 
common in elderly patients [1], and so it is not surpris-
ing that (older) patients associated with community-
based residential care had a different distribution of 
ribotypes compared with community residents living 
in their own home. Furthermore, we found that CDI 
cases either resident in their own home or with no evi-
dence of hospital stay within the previous 12 months 
were associated with higher relative diversity indices 
than either those residing in care homes or admitted to 
hospital within the previous six months. More simply, 
patients with less recent contact with hospitals were 
more likely to be affected by a more diverse range of 
C. difficile strains than those with more recent contact, 
presumably reflecting a lower risk of contact with epi-
demic strains. We did not collect information on CDI 
outbreaks as this was beyond the scope of the study.
While antibiotic exposure is a key risk factor for CDI 
[1,31-33], our study has again demonstrated that over 
a third of CA-CDI cases were associated with no recent 
history of a prescribed antibiotic, as seen in other 
studies [22,34-37]. Indeed, we found that CA-CDI cases 
were nearly twice as likely to have had no antibiotics 
preceding infection than HA-CDI cases (p < 0.0001). 
Certain ribotypes notably 001, 002 and 015 were more 
commonly associated with patients receiving no anti-
biotics before their infection. Such data indicate that 
antibiotic history might be less of a prerequisite for 
infection with these C. difficile ribotypes and alterna-
tive factors support the spread of these ribotypes in 
the community setting. Other risk factors associated 
with CA-CDI have been extensively reported, includ-
ing gastric acid suppressants and contact with infants 
under two years-old [34,38]. However, no data cur-
rently exist to associate such factors with CDI due to 
ribotypes 002 and 015 in the community setting.
There is increasing evidence linking CDI to environmen-
tal sources including water and food [39-41]. Although 
these studies have identified clinically relevant 
ribotypes, notably including 078, in foodstuffs, food-
borne transmission of C. difficile has not been demon-
strated. For example, we recently found no differences 
between hospital and community onset of infection, or 
in food or environmental exposures between ribotype 
078 CDI cases and those caused by other ribotypes 
[42]. However, conditional logistic regression mod-
elling adjusting for age found that ribotype 078 CDI 
cases were markedly more likely than other cases to 
report prior antibiotic exposure (odds ratio: 5.1 (95% 
CI: 1.6–16.3); p = 0.002) [42]. More studies employing 
WGS are needed to understand the significance of com-
munity C. difficile reservoirs to human disease. This is 
probably best achieved early as new strains emerge, 
not least because once established it becomes more 
difficult to untangle true risk factors from confounding 
issues. The emergence of ribotype 244 in Australasia 
is a good example of the use of WGS to map the spread 
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of this new clone primarily causing CA-CDI, although a 
proven community reservoir remains elusive [43].
In summary, while there were examples of ribotypes 
that significantly predominated in CA- or HA-CDIs, we 
found very similar ribotype diversity indices, ranking 
and relative strain prevalences in these two groups. 
Ribotype 002 was associated with CA-CDI, and there 
was a clear predominance of epidemic ribotypes, nota-
bly 027 and 001, in patients associated with commu-
nity-based residential care compared with those living 
in their own home. CA-CDI cases were nearly twice as 
likely to have had no antibiotics preceding infection 
than corresponding HA-CDI cases during the same 
period. Our nationally sourced data emphasise the 
close interplay between hospital and community set-
tings, particularly when there are relatively low levels 
of hospital-based case-to-case transmission of C. dif-
ficile and thus less dominance of epidemic C. difficile 
clones. 
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